A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
|Poll|August 20, 2014
A 60-Year-Old Man Presents With Plantar Hyperkeratosis & Erythema
Author(s)Shivani Tripathi, MD, Milan Anadkat, MD
A 60-year-old man presents with localized tender plaques of hyperkeratosis and a surrounding erythematous halo on the weight-bearing plantar aspect of his feet after beginning cancer treatment. Which medication is responsible for this cutaneous presentation and what is the name of this reaction?
Advertisement
A 60-year-old man presents with localized tender plaques of hyperkeratosis and a surrounding erythematous halo on the weight-bearing plantar aspect of his feet after beginning cancer treatment.
What is your diagnosis?
Advertisement
Related to this article
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5